Competitor Analysis: Cardiometabolic Peptides
Competitor Analysis: Cardiometabolic Peptides
The Competitive Intelligence Report Cardiometabolic Peptides as of November 2014 provides a competitor analysis in the development pipeline of peptide therapeutics for treatment of diabetes, obesity and atherosclerosis. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of currently active projects in research and development for novel cardiometabolic peptides. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Cardiometabolic Peptides as of November 2014 provides a competitor analysis in the development pipeline of peptide therapeutics for treatment of diabetes, obesity and atherosclerosis. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of currently active projects in research and development for novel cardiometabolic peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- 2013 Sales of Major CardioMetabolic Peptides
- Selective Peptide GLP-1 Receptor Agonists for CardioMetalic Diseases
- Dual Target Peptide GLP-1 Agonists for CardioMetabolic Diseases
- Other Peptides for Diabetes
- Other Peptides for Obesity & Lipodystrophy
- Other Peptides for Diabetes and Obesity & Cardiometabolic Disease
- Peptides for Atherosclerosis
- Corporate Cardiometabolic Peptide R&D Pipelines
